E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
First degree burn injury in healthy volunteers |
|
E.1.1.1 | Medical condition in easily understood language |
A light heat injury (reddening of the skin, pain with touch of the area) in healthy volunteers |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020573 |
E.1.2 | Term | Hyperalgesia |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective is to evaluate if naloxone can re-instate secondary hyperalgesia areas 7 days after a burn injury |
|
E.2.2 | Secondary objectives of the trial |
The secondary objective is to examine if naloxone can re-instate hyperalgesia, evaluated by thermal (warmth detection thresholds, heat pain thresholds) and mechanical (pin-prick thresholds) after a first degree burn injury. Psychometrics (Hospital Anxiety and Depression Scale [HADS], Pain Catastrophizing Scale [PCS]) and correlation with pain-related variables. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Prestudy to: "The effect of late high-dose naloxone-infusion on secondary hyperalgesia following a first degree heat injury".
22 of April 2013
Unblinded administration of naloxone 2 mg/kg to 3 healthy volunteers. The objectives are feasibility and tolerance to administration of high-dose naloxone. |
|
E.3 | Principal inclusion criteria |
male, healthy, age between 20 and 35, BMI between 18 and 30, verbal and written informed consent, normal cardiac ultrasound examination, normal ECG |
|
E.4 | Principal exclusion criteria |
unable to cooperate, not able to understand Danish or English, neurological disease, psychiatric disease, drug or alcohol abuse, chronic pain state, positive urine test for opioids (morphine, methadone, buprenorphine), skin infection in the test areas (lower leg), allergy to morphine-related drugs, chronic pain medication. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary outcome is areas of secondary hyperalgesia |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Secondary hyperalgesia areas are evaluated before and 1,2,3,165,168 + 168½ hrs after the burn injury. |
|
E.5.2 | Secondary end point(s) |
Thermal and mechanical thresholds, and, psychometrics |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Thermal thresholds are assessed at baseline and 1,2,3 hours after the burn injury.
Mechanical thresholds are assessed at baseline and 1,2,3,165,168 + 168½ hrs after the burn injury.
Psychometrics are obtained at baseline. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Interim-analysis after first 6 participants. These data are not included in final analysis. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 13 |